The purpose of this study was the evaluation of the predictive value of ambulatory BP monitoring (ABPM) for the development of drug-treated hypertension in subjects with high-normal BP (HNBP: ≥130/85 and 2; 66.2% vs. 33.9%) and hypercholesterolemia (= total cholesterol > 230 mg/dl; 32.3% vs. 1.7%). Prevalence of overt diabetes mellitus was not statistically different between groups. All the subjects, who had normal physical examination and ECG and no history of cardiovascular disease, underwent ABPM by means of Spacelabs 90207 recorders. All ABPM variables were statistically (at least p135/85 mmHg) mean daytime ABP (p<0.01). Univariate analysis was performed by means of Chi-square and Student's t tests to evaluate variables which could be associated with the development of drug-treated hypertension in the follow-up. A p<0.05 was accepted as statistically significant. After an average follow-up of 103± 28 months, 27 subjects (39.7%; 17 M and 10 F) in the HNBP group and 4 subjects (6.8%; 1 M and 3 F) in the NBP group developed drug-treated hypertension (p<0.01). An elevated daytime ABP correctly predicted development of drug-treated hypertension in 17/21 subjects (81%) of the HNBP group and in the only subject of the NBP group. Development of drug-treated hypertension was associated with higher office and ambulatory BP (p<0.01) and pulse pressures (p<0.05), longer follow-up (p<0.05) and higher prevalence of hypercholesterolemia and smoking (p135/85 mmHg (following ASH and JNC VI recommmendations). ABPM appears a useful clinical tool in the early diagnosis of hypertension in subjects with metabolic risk factors and smoking.